Curr Hypertens Rep. 2020 Apr 14;22(5):37. doi: 10.1007/s11906-020-1034-8.

Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia.

Suvakov S^1,2, Richards C³, Nikolic V⁴, Simic T^2,5, McGrath K³, Krasnodembskaya A⁶, McClements L⁷.

Abstract

PURPOSE OF REVIEW:

Preeclampsia is a dangerous pregnancy condition affecting both the mother and offspring. It is a multifactorial disease with poorly understood pathogenesis, lacking effective treatments. Maternal immune response, inflammation and oxidative stress leading to endothelial dysfunction are the most prominent pathogenic processes implicated in preeclampsia development. Here, we give a detailed overview of the therapeutic applications and mechanisms of mesenchymal stem/stromal cells (MSCs) as a potential new treatment for preeclampsia.

RECENT FINDINGS:

MSCs have gained growing attention due to low immunogenicity, easy cultivation and expansion in vitro. Accumulating evidence now suggests that MSCs act primarily through their secretomes facilitating paracrine signalling that leads to potent immunomodulatory, pro-angiogenic and regenerative therapeutic effects. MSCs have been studied in different animal models of preeclampsia demonstrating promising result, which support further investigations into the therapeutic effects and mechanisms of MSC-based therapies in preeclampsia, steering these therapies into clinical trials.